A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors

The purpose of this study is to find out whether IV injection of HCB101 is an effective treatment for different types of advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma and what side effects (unwanted effects) may occur in subjects aged 18 years old and above.

Trial Details

NCT ID
NCT05892718
Phase
PHASE1
Sponsor
FBD Biologics Limited
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • HCB101
Locations (sample)
  • Port Saint Lucie, Florida, United States|27.29393,-80.35033
  • Huntersville, North Carolina, United States|35.41069,-80.84285
  • Greenville, South Carolina, United States|34.85262,-82.39401
  • Dallas, Texas, United States|32.78306,-96.80667
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Able to understand and willing to sign the ICF.
  • Male and female subjects of ≥18 years of age.
  • Histologically/cytologically confirmed, locally advanced solid tumor: subjects with histologically or cytologically confirmed advanced solid tumors…
  • For subjects with advanced solid tumor - must have at least 1 measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST)…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →